Filed pursuant to Rule 424(b)(3)
Registration No. 333-234366
PROSPECTUS - DATED NOVEMBER 19, 2019
PREDICTIVE ONCOLOGY INC.
1,139,423 Shares
Common Stock
This prospectus relates to the offer and resale of up to 1,139,423
shares of our common stock, par value $0.01 per share, by Oasis Capital, LLC (“Oasis Capital”), the selling stockholder.
Oasis Capital has agreed to purchase from us pursuant to the terms and conditions of an Equity Purchase Agreement that we entered
into with Oasis Capital on October 24, 2019 (the “Equity Purchase Agreement”). Subject to the terms and conditions
of the Equity Purchase Agreement, we have the right to “put,” or sell, at our discretion, up to $15,000,000 worth of
shares of our common stock to Oasis Capital. This arrangement is also sometimes referred to herein as the “Equity Line”
or the “Oasis Equity Line.”
For more information about the selling stockholder, please see the
section of this prospectus entitled “Selling Stockholder” beginning on page 15.
The selling stockholder may sell any shares offered under this prospectus
at fixed prices, prevailing market prices at the time of sale, at varying prices or negotiated prices.
Oasis Capital is an “underwriter” within the meaning
of the Securities Act of 1933, as amended (the “Securities Act”), in connection with the resale of our common stock
under the Equity Line, and any broker-dealers or agents that are involved in such resales may be deemed to be “underwriters”
within the meaning of the Securities Act in connection therewith. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. For more information, please see the section of this prospectus titled “Plan of Distribution”
beginning on page 17.
We will not receive any proceeds from the resale of shares of common
stock by the selling stockholder. We will, however, receive proceeds from the sale of shares directly to Oasis Capital pursuant
to the Equity Line.
Our common stock is listed on the Nasdaq Capital Market under the symbol “POAI.”
On October 28, 2019, the last reported per share price of our common stock on the Nasdaq Capital Market was $4.02 per share, as
adjusted for a one-for-ten reverse stock split effective for trading purposes as of October 29, 2019 (the “Reverse Split”).
The numbers of shares of common stock and prices per share indicated in this prospectus have been adjusted to reflect the Reverse
Split.
Investing in our common stock involves a high degree of risk. Before deciding
whether to invest in our securities, you should consider carefully the risks that we have described beginning on page 6 of
this prospectus under the caption “Risk Factors” and in the documents incorporated by reference into this
prospectus.
Neither the Securities and Exchange Commission nor any state securities commission
has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to
the contrary is a criminal offense.
The date of this prospectus is November 19,
2019.
Table of Contents
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that
we have filed with the Securities and Exchange Commission (the “SEC”) pursuant to which the selling stockholder named
herein may, from time to time, offer and sell or otherwise dispose of the securities covered by this prospectus. You should not
assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front
cover of this prospectus or that any information we have incorporated by reference is correct on any date subsequent to the date
of the document incorporated by reference, even though this prospectus is delivered or securities are sold or otherwise disposed
of on a later date. It is important for you to read and consider all information contained in this prospectus, including the Information
Incorporated by Reference herein, in making your investment decision. You should also read and consider the information in the
documents to which we have referred you under the captions “Where You Can Find More Information” and “Incorporation
of Information by Reference” in this prospectus.
Neither we nor the selling stockholder have authorized
any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated
by reference in this prospectus. You should not rely upon any information or representation not contained or incorporated by reference
in this prospectus. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our securities
other than the securities covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer
to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.
Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves
about, and to observe, any restrictions as to the offering and the distribution of this prospectus applicable to those jurisdictions.
We further note that the representations, warranties
and covenants made in any agreement that is filed as an exhibit to any document that is incorporated by reference in the prospectus
were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk
among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such
representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties
and covenants should not be relied on as accurately representing the current state of our affairs.
Unless the context otherwise requires, references in
this prospectus to “Predictive,” the “Company,” “we,” “us,” and “our”
refer to Predictive Oncology Inc.
You should rely only on the information contained or incorporated by reference, as
applicable, in this prospectus, any prospectus supplement, or other offering materials related to an offering of securities described
in this prospectus. We have not authorized anyone to provide you with different or additional information. If anyone provides you
with different or additional information, you should not rely on it.
You should not assume that the information contained or incorporated by reference,
as applicable, in this prospectus, any prospectus supplement, or other offering materials related to an offering of securities
described in this prospectus is accurate as of any date other than the date of that document. Neither the delivery of this prospectus,
any prospectus supplement or other offering materials related to an offering of securities described in this prospectus, nor any
distribution of securities pursuant to this prospectus, any such prospectus supplement, or other offering materials shall, under
any circumstances, create any implication that there has been no change in the information set forth or incorporated by reference,
as applicable, in this prospectus, any such prospectus supplement or other offering materials since the date of each such document.
Our business, financial condition, results of operations and prospects may have changed since those dates.
This prospectus does not constitute, and any prospectus supplement or other offering
materials related to an offering of securities described in this prospectus will not constitute, an offer to sell, or a solicitation
of an offer to purchase, the offered securities in any jurisdiction to or from any person to whom or from whom it is unlawful to
make such offer or solicitation in such jurisdiction.
THE COMPANY
This summary contains basic information about us. You should read the entire prospectus
carefully, especially the risks of investing in our securities discussed under “Risk Factors.” Some of the statements
contained in this prospectus, including statements under this summary and “Risk Factors” are forward-looking statements
and may involve a number of risks and uncertainties. We note that our actual results and future events may differ significantly
based upon a number of factors. You should not put undue reliance on the forward-looking statements in this document, which speak
only as of the date on the cover of this prospectus. References to “we,” “our,” “us,” the “Company,”
or “Predictive” refer to Predictive Oncology Inc., a Delaware corporation.
Business Overview
Predictive Oncology Inc. (NASDAQ: POAI) operates in two business areas: first, applying
artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and
clinicians as well as clients in the pharmaceutical, diagnostic and biotech industries, and second, production of the FDA-approved
STREAMWAY® System for automated, direct-to-drain medical fluid disposal.
Predictive’s medicine business is committed to improving the effectiveness of cancer
therapy using the power of artificial intelligence (AI) applied to rich data disease databases. This business launched with Predictive’s
acquisition of 25% of the capital stock of Helomics Holding Corporation (“Helomics”), a precision medicine company
and integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical,
diagnostic and academic organizations to bring innovative clinical products and technologies to the marketplace. In addition to
its proprietary precision diagnostics for oncology, Helomics offers boutique Contract Research Organization (CRO) services that
leverage their patient-derived tumor models, coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical),
and a proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.
Predictive has also formed a subsidiary, TumorGenesis, to pursue a new rapid approach
to growing tumors in the laboratory, which essentially “fools” the cancer cells into thinking they are still growing
inside the patient. Predictive and Helomics have also announced a proposed joint venture with GLG Pharma focused on using their
combined technologies to bring personalized medicines and testing to ovarian and breast cancer patients, especially those who present
with ascites fluid (over one-third of patients). The growth strategy in this business includes securing new partnerships and considering
acquisitions in the precision medicine space.
On October 26, 2018, Predictive entered into an Amended and Restated Agreement and Plan
of Merger (the “Merger Agreement”) with Helomics Acquisition, Inc., a wholly owned subsidiary of the Company (“Merger
Sub”), and Helomics. The Merger Agreement contemplated a forward triangular merger whereby Helomics would merge with and
into Merger Sub, with Merger Sub surviving the Merger as a wholly-owned operating subsidiary of Predictive (the “Merger”).
The Merger was completed on April 4, 2019 and provided the Company, as the sole owner of Helomics, with full access to Helomics’
suite of AI, precision diagnostic and integrated CRO capabilities, which improve patient care and advance the development of innovative
clinical products and technologies for the treatment of cancers.
Sold through the Skyline Medical business of Predictive Oncology, The STREAMWAY System
virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare
environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an
exposure risk and potential liability. Skyline Medical’s STREAMWAY System fully automates the collection, measurement, and
disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance
with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy
departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate
the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S.
For more information regarding Predictive’s businesses, please carefully consider
the information contained in our periodic reports filed with the SEC, which are incorporated by reference into this prospectus.
Before making an investment decision, you should carefully consider such information as well as other information we include or
incorporate by reference into this prospectus.
Recent Developments
Special Stockholders Meeting. On October 23, 2019, we held a special meeting of
stockholders at which the following actions were taken: (1) approval of an amendment of the Company’s certificate of incorporation
to effect a reverse stock split of the outstanding shares of its common stock at a ratio of not less than one-for-two (1:2) and
not more than one-for-fifteen (1:15) (the “Reverse Split Proposal”); (2) approval, pursuant to Nasdaq Listing Rule
5635, of the issuance of shares of common stock of the Company in excess of applicable share caps upon conversion of the outstanding
shares of Series E Convertible Preferred Stock; and (3) approval, pursuant to Nasdaq Listing Rule 5635, of the issuance of shares
of common stock of the Company pursuant to an equity line of credit arrangement of up to $15.0 million, when and if negotiated
with a specific investor.
Reverse Stock Split. On October 25, 2019, following the approval of the Reverse
Split Proposal, we filed an amendment to our Amended and Restated Certificate of Incorporation in order to effect a one-for-ten
reverse stock split (the “Reverse Split”), effective for trading purposes on October 29, 2019. The number of authorized
shares of common stock remains at 100,000,000. The purpose of the Reverse Split is to prevent our stock from being delisted from
Nasdaq. As described in a Current Report on Form 8-K filed on May 17, 2019, we must regain compliance with Nasdaq’s minimum
bid price requirement no later than November 11, 2019, and we believe the Reverse Split is necessary to assure compliance with
such requirement.
The numbers of shares of common stock and prices per share indicated in this prospectus
have been adjusted to reflect the Reverse Split.
Equity Purchase Agreement. On October 24, 2019 (the “Execution
Date”), the Company entered into an Equity Purchase Agreement (the “Equity Purchase Agreement”) with Oasis Capital,
LLC (“Oasis Capital”), providing for an equity financing facility (the “Equity Line”). The Equity Purchase
Agreement provides that, upon the terms and subject to the conditions in the Equity Purchase Agreement, Oasis Capital is committed
to purchase shares (“Put Shares”) having an aggregate value of up to $15.0 million (the “Maximum Commitment Amount”)
of our common stock during the period (the “Commitment Period”) commencing on the Execution Date, and ending on the
earlier of (i) the date on which Oasis Capital shall have purchased Put Shares equal to the Maximum Commitment Amount, (ii) October
24, 2022, or (iii) written notice of termination by the Company to Oasis Capital (which shall not occur at any time that Oasis
Capital holds any of the Put Shares). In consideration for Oasis Capital’s execution and delivery of, and performance under
the Equity Purchase Agreement, the Company also issued to Oasis Capital 104,652 shares (the “Commitment Shares”).
Under the terms of the Equity Purchase Agreement,
Oasis Capital will not be obligated to purchase Put Shares unless and until certain conditions (“Closing Conditions”)
are met, including but not limited to a registration statement on Form S-1 being effective which registers Oasis Capital’s
resale of any Put Shares purchased by it under the Equity Line and the Commitment Shares. From time to time during the Commitment
Period, provided that the Closing Conditions are satisfied, we may, in our sole discretion, provide Oasis Capital with a put notice
(each, a “Put Notice”), to purchase a specified number of Put Shares. Each Put Notice may be either an Option 1 Put
Notice or an Option 2 Put Notice.
Subject to certain limitations and conditions,
an “Option 1 Put Notice” will require Oasis Capital to purchase the specified number of Put Shares up to the Option
1 Maximum Put Amount. The “Option 1 Maximum Put Amount” means: (a) if, on the trading day when the Put Notice is delivered
(the “Put Date”), the closing bid price of our common stock on Nasdaq is below $10.00, then “Option 1 Maximum
Put Amount” shall mean the lesser of (i) 10,000 shares, or (ii) twenty percent (20%) of the average trading volume of our
common stock in the ten (10) trading days immediately preceding the respective Put Date (the “Average Daily Trading Volume”);
and (b) if, on the Put Date, the closing bid price of our common stock on Nasdaq is $10.00 or greater but less than $15.00, then
“Option 1 Maximum Put Amount” shall mean the lesser of (i) 12,500 shares, or (ii) twenty percent (20%) of the Average
Daily Trading Volume; and (c) if, on the Put Date, the closing bid price of our common stock on Nasdaq is $15.00 or greater but
less than $20.00, then “Option 1 Maximum Put Amount” shall mean the lesser of (i) 15,000 shares, or (ii) twenty percent
(20%) of the Average Daily Trading Volume; and (d) if, on the Put Date, the closing bid price of our common stock on Nasdaq is
$20.00 or greater, then “Option 1 Maximum Put Amount” shall mean the lesser of (i) 20,000 shares, or (ii) twenty percent
(20%) of the Average Daily Trading Volume. The purchase price (the “Option 1 Purchase Price”) will be equal to the
lesser of (i) the one (1) lowest traded price of our common stock on Nasdaq on the date on which Oasis Capital receives the Put
Shares (the “Clearing Date”), or (ii) the average of the three (3) lowest closing sale prices of our common stock on
Nasdaq during the twelve (12) consecutive trading days immediately preceding the Clearing Date associated with the applicable Put
Notice during which the Option 1 Purchase Price of our common stock is valued.
The Company may only deliver an Option 2 Put
Notice if an Option 1 Put has been previously and effectively processed and its clearing date is the same day as the Put Notice
for the subject Option 2 Put. Subject to certain other limitations and conditions, an “Option 2 Put Notice” will require
Oasis Capital to purchase the specified number of Put Shares up to up to the Option 2 Maximum Put Amount. The “Option 2 Maximum
Put Amount” means the lesser of (i) such amount that equals ten percent (10%) of the daily trading volume of our common stock
on the Put Date, and (ii) Two Hundred Thousand Dollars ($200,000.00). The purchase price (the “Option 2 Purchase Price”)
will be equal to the lesser of (i) 91% of the one (1) lowest traded price of our common stock on Nasdaq during the ten (10) consecutive
trading days immediately preceding the trading day associated with the applicable Put Notice during which the Option 2 Purchase
Price of our common stock is valued, or (ii) 93% of the volume weighted average price on the Clearing Date, or (iii) 93% of the
closing bid price of our common stock on Nasdaq on the Clearing Date.
The Equity Purchase Agreement contains customary
representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the
Company, including for liabilities under the Securities Act, other obligations of the parties and termination provisions.
With regard to the purchase and resale of the
Put Shares, Oasis Capital is an “underwriter” within the meaning of the Securities Act of 1933, as amended. Any broker-dealers
or agents that are involved in resales of the Put Shares may be deemed “underwriters.” The Company will receive net
proceeds from the sale of the Put Shares directly from Oasis Capital pursuant to the Equity Purchase Agreement, however, the Company
will not receive any proceeds from the resale of the Put Shares by Oasis Capital thereafter.
The foregoing description of the terms and conditions
of the Equity Purchase Agreement is not complete and is qualified in its entirety by the full text of the Equity Purchase Agreement,
which was filed as Exhibit 10.1 to a Current Report on Form 8-K filed on October 25, 2019 and is incorporated herein by this reference.
Registration Rights Agreement. In connection with the Equity
Line, we also entered into a Registration Rights Agreement, dated the Execution Date, with Oasis Capital (the “Registration
Rights Agreement”), pursuant to which we agreed to register for resale any Put Shares purchased by Oasis Capital under the
Equity Line and the Commitment Shares (the “Registrable Securities”) in an initial registration statement (the “Initial
Registration Statement”) on Form S-1 to be filed with the Securities and Exchange Commission (the “SEC”) by the
fifth day after the Execution Date. The Company is obligated to use its reasonable best efforts to have the Initial Registration
Statement and any amendment thereto declared effective by the SEC at the earliest possible date. In the event the number of shares
available under the Initial Registration Statement is insufficient to cover all of the Registrable Securities, the Company must
amend the Initial Registration Statement or file a new registration statement, so as to cover all of the Registrable Securities
as soon as practicable, but in any event not later than ten (10) business days after the necessity therefor arises, subject to
any limits that may be imposed by the SEC pursuant to Rule 415 under the Securities Act of 1933, as amended. As explained above,
the effectiveness of the Initial Registration Statement is a condition precedent to our ability to sell Put Shares to Oasis Capital
under the Equity Purchase Agreement.
The foregoing description of the terms and conditions
of the Registration Rights Agreement is not complete and is qualified in its entirety by the full text of the Registration Rights
Agreement, which was filed as Exhibit 10.2 to a Current Report on Form 8-K filed on October 25, 2019 and is incorporated herein
by this reference.
Risks
We are subject to a number of risks. You should read the “Risk Factors” section
of this prospectus beginning on page 6 for a discussion of factors to consider carefully before deciding to invest in shares
of our common stock.
Corporate Information
We were originally incorporated on April 23, 2002 in Minnesota as BioDrain Medical, Inc.
Effective August 6, 2013, BioDrain Medical, Inc. changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of
Merger effective December 16, 2013, Skyline Medical Inc. merged with and into a Delaware corporation with the same name that was
its wholly-owned subsidiary, with such Delaware corporation as the surviving corporation of the merger. On August 31, 2015, Skyline
Medical Inc. completed a successful offering and concurrent uplisting to The Nasdaq Capital Market. On February 1, 2018, Skyline
Medical Inc. filed with the Secretary of State of Delaware a Certificate of Amendment to the Certificate of Incorporation to change
its corporate name from Skyline Medical Inc. to “Precision Therapeutics Inc.” On June 10, 2019, Precision Therapeutics
Inc. filed with the Secretary of State of Delaware a Certificate of Amendment to the Certificate of Incorporation to change its
corporate name from Precision Therapeutics Inc. to “Predictive Oncology Inc.” Because of this change, the Company’s
common stock traded under the new ticker symbol “POAI,” effective June 13, 2019. Skyline Medical remains as a division
of Predictive and principally manufactures the STREAMWAY System.
Our address is 2915 Commers Drive, Suite 900, Eagan, Minnesota 55121. Our telephone number
is (651) 389-4800, and our website address is www.precisiontherapeutics.com. The information contained on, or that can be accessed
through, our website is not part of this prospectus.
OFFERING SUMMARY
Common stock that may be offered by selling stockholder
|
|
1,139,423 shares
|
|
|
|
Common stock outstanding before this offering
|
|
3,887,986 shares (1)
|
|
|
|
Common stock to be outstanding after this offering
|
|
5,027,409 shares (2)
|
|
|
|
Use of proceeds
|
|
We will not receive any proceeds from the resale or other disposition of the shares covered by this prospectus by the selling stockholder. We will receive proceeds from the sale of shares to Oasis Capital. Oasis Capital has committed to purchase up to $15,000,000 worth of shares of our common stock (the “Put Shares”) over a period of time terminating on the earlier of (a) the date on which Oasis Capital shall have purchased Put Shares for an aggregate purchase price of $15,000,000, (b) October 24, 2022 and (c) written notice of termination by the Company to Oasis Capital (which shall not occur at any time that Oasis Capital holds any of the Put Shares).
|
|
|
|
|
|
In the case of an Option 1 Put, Oasis Capital will
pay a purchase price equal to the lesser of (i) the one (1) lowest traded price of our common stock on Nasdaq on the date on which
Oasis Capital receives the Put Shares, or (ii) the average of the three (3) lowest closing sale prices of the common stock on
Nasdaq during the twelve (12) consecutive trading days immediately preceding the Clearing Date. In the case of an Option 2 Put,
Oasis Capital will pay a purchase price equal to the lesser of (i) 91% of the one (1) lowest traded price of our common stock
on Nasdaq during the ten (10) consecutive trading days immediately preceding the trading day associated with the applicable put
notice, or (ii) 93% of the volume weighted average price on the Clearing Date, or (iii) 93% of the closing bid price of our common
stock on Nasdaq on the Clearing Date.
In order to exercise the put, certain conditions must be
met at each put notice date including, but not limited to a registration statement on Form S-1 being effective which registers
Oasis Capital’s resale of any Put Shares purchased by it and the 104,652 shares of our common stock we issued to Oasis Capital
upon signing the Equity Purchase Agreement (the “Commitment Shares”).
|
|
|
|
|
|
For further information, see “The Offering” beginning on page 13.
|
|
|
|
Plan of Distribution
|
|
The selling stockholder may, from time to time, sell any or all of their shares of our common stock on the stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices.
|
|
|
|
|
|
For further information, see “Plan of Distribution”
beginning on page 17.
|
|
|
|
Risk factors
|
|
You should read the “Risk Factors” section of this prospectus and the other information in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.
|
(1)
|
The number of shares of our common stock issued and outstanding as of October 29, 2019. The numbers of shares of common stock and prices per share indicated in this preliminary prospectus have been adjusted in order to reflect a the Reverse Split.
|
|
|
(2)
|
Assumes the issuance of the 1,139,423 shares that are issuable under the Equity Purchase Agreement with Oasis Capital and offered under this prospectus.
|
RISK FACTORS
An investment in our securities involves a number of risks. Before deciding to invest in our securities,
you should carefully consider the risks described below and discussed under the section captioned “Risk Factors” contained
in our Annual Report on Form 10-K for the year ended December 31, 2018 and our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2019, which are incorporated by reference in this prospectus, together with the additional risk factor described
under “Additional Risk Factor” below, other information in this prospectus, the information and documents incorporated
by reference herein, and in any prospectus supplement or free writing prospectus that we have authorized for use in connection
with an offering. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow
could be harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your
investment. The risks described in the documents referenced above are not the only ones that we face. Additional risks not presently
known to us or that we currently deem immaterial may also affect our business.
Additional Risk Factor
The Company’s certificate of incorporation, as amended, provides that, to
the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the exclusive forum for certain legal
actions between the Company and its stockholders, which could limit the Company’s stockholders’ ability to obtain a
judicial forum viewed by the stockholders as more favorable for disputes with the Company or the Company’s directors, officers
or employees.
The Company’s certificate of incorporation, as amended, provides that, to the fullest extent permitted
by law, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding
brought on behalf of the corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director or officer
of the corporation to the corporation or the corporation’s stockholders, (iii) any action asserting a claim against the corporation
arising pursuant to any provision of the General Corporation Law or the corporation’s Certificate of Incorporation or Bylaws,
or (iv) any action asserting a claim against the corporation governed by the internal affairs doctrine. This exclusive forum provision
does not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended. It could
apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts
claims under the Securities Act of 1933, as amended (the “Securities Act”), inasmuch as Section 22 of the Securities
Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created
by the Securities Act or the rule and regulations thereunder. There is uncertainty as to whether a court would enforce such provision
with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the
federal securities laws and the rules and regulations thereunder.
Any person or entity purchasing or otherwise acquiring any interest in any of our securities
shall be deemed to have notice of and consented to these provisions. These exclusive-forum provisions may limit a stockholder’s
ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers or other employees,
which may discourage lawsuits against us and our directors, officers and other employees.
If a court were to find the choice of forum provision contained in our certificate of
incorporation, as amended, to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving
such action in other jurisdictions, which could harm our business, results of operations, and financial condition. Even if we are
successful in defending against these claims, litigation could result in substantial costs and be a distraction to the Company’s
management.
NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some of the statements made in this prospectus are “forward-looking statements”
that indicate certain risks and uncertainties related to the Company, many of which are beyond the Company’s control. The
Company’s actual results could differ materially and adversely from those anticipated in such forward-looking statements
as a result of certain factors, including those set forth below and elsewhere in this report. Important factors that may cause
actual results to differ from projections include:
|
•
|
The Company will not be able to continue operating without additional financing;
|
|
|
|
|
•
|
Current negative operating cash flows;
|
|
|
|
|
•
|
The terms of any further financing, which may be highly dilutive and may include onerous terms;
|
|
|
|
|
•
|
Risks related to the recent Merger with Helomics; possible failure to realize anticipated benefits of the Merger; costs associated with the Merger may be higher than expected; the Merger may result in the disruption of the Company’s and Helomics’ existing businesses; and distraction of management and diversion of resources; delay in completion of the merger may significantly reduce the expected benefits;
|
|
|
|
|
•
|
Risks related to the Company’s proposed joint ventures, including the need to negotiate the definitive agreements for the joint ventures; possible failure to realize anticipated benefits of the joint ventures; and costs of providing funding to the joint ventures
|
|
•
|
Current negative operating cash flows, as well as the impact on our cash levels of advances to our strategic partners and possible future advances to such organizations or others;
|
|
•
|
The terms of any further financing, which may be highly dilutive and may include onerous terms;
|
|
•
|
Risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property;
|
|
•
|
The impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology;
|
|
•
|
Inability to raise sufficient additional capital to operate our business;
|
|
•
|
Risk that we never become profitable if our product is not accepted by potential customers;
|
|
•
|
Possible impact of government regulation and scrutiny;
|
|
•
|
Unexpected costs and operating deficits, and lower than expected sales and revenues, if any;
|
|
•
|
Adverse economic conditions;
|
|
•
|
Adverse results of any legal proceedings;
|
|
•
|
The volatility of our operating results and financial condition;
|
|
•
|
Inability to attract or retain qualified senior management personnel, including sales and marketing personnel;
|
|
•
|
The potential delisting of our common stock from the Nasdaq Capital Market if we do not continue to meet applicable listing standards; and
|
|
•
|
Other specific risks that may be alluded to in this prospectus or documents incorporated herein.
|
In some cases, you can identify forward-looking statements by terms such as “may”, “will”,
“should”, “could”, “would”, “expects”, “plans”, “anticipates”,
“believes”, “estimates”, “projects”, “predicts”, “potential” and similar
expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future
events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue
reliance on these forward-looking statements. We discuss many of these risks in greater detail under the heading “Risk Factors”
beginning on page 6 of this prospectus and in our SEC filings. Also, these forward-looking statements represent our estimates and
assumptions only as of the date of the document containing the applicable statement.
You should read this prospectus, the documents we have filed with the SEC that are incorporated
by reference and any free writing prospectus that we have authorized for use in connection with this offering completely and with
the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking
statements in the foregoing documents by these cautionary statements.
Information regarding market and industry statistics contained in this prospectus is
included based on information available to the Company that it believes is accurate. It is generally based on academic and other
publications that are not produced for purposes of securities offerings or economic analysis. The Company has not reviewed or included
data from all sources, and the Company cannot assure potential investors of the accuracy or completeness of the data included in
this prospectus. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications
and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and
services. The Company has no obligation to update forward-looking information to reflect actual results or changes in assumptions
or other factors that could affect those statements.
USE OF PROCEEDS
We will not receive any proceeds from the sale of the shares of our common stock by the
selling stockholder. However, we will receive proceeds from the sale of the shares of our common directly to Oasis Capital pursuant
to the Equity Purchase Agreement. We will use these proceeds for general corporate and working capital purposes, or for other purposes
that our board of directors, in its good faith, deems to be in the best interest of our Company. We have agreed to bear the expenses
relating to the registration of the offer and resale by the selling stockholder of the shares being offered hereby.
DESCRIPTION OF CAPITAL STOCK
The following description summarizes the material terms of our
capital stock. This summary is, however, subject to the provisions of our certificate of incorporation and bylaws. For greater
detail about our capital stock, please refer to our certificate of incorporation and bylaws. For information about matters to be
considered at a special stockholders meeting on October 23, 2019, which will affect our capital stock, see “The Company –
Planned Special Stockholders Meeting.”
General
We are authorized to issue 100,000,000 shares of common stock, par value $0.01 per share,
and 20,000,000 shares of preferred stock, of which 2,300,000 shares are authorized as Series B Convertible Preferred Stock, par
value $0.01 per share, 3,500,000 shares are authorized as Series D Convertible Preferred Stock, par value $0.01 per share and
350 shares are authorized as Series E Convertible Preferred Stock, par value $0.01 per share.
Common Stock
As of October 28, 2019, we had 3,887,986 shares of common stock outstanding (adjusted
to reflect the Reverse Split) held by approximately 165 stockholders of record
The holders of common stock are entitled to one vote per share on all matters to be voted
upon by the stockholders, provided that no proxy shall be voted if executed more than three years prior to the date of the stockholders’
meeting except if such proxy provides for a longer period. Holders of our common stock do not have cumulative voting rights.
The holders of common stock are entitled to receive ratably any dividends that may be
declared from time to time by our board of directors out of funds legally available for that purpose. In the event of our liquidation,
dissolution or winding up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities.
The common stock has no preemptive or conversion rights or other subscription rights and there are no redemption provisions applicable
to our common stock. All outstanding shares of common stock are fully paid and non-assessable, and the shares of common stock offered
hereby will be fully paid and not liable for further call or assessment.
Except for directors, who are elected by receiving the highest number of affirmative
votes of the shares entitled to be voted for them, or as otherwise required by Delaware law, and subject to the rights of the holders
of preferred stock then outstanding (if any), all stockholder action is taken by the vote of a majority of the issued and outstanding
shares of common stock present at a meeting of stockholders at which a quorum consisting of a majority of the issued and outstanding
shares of common stock is present in person or proxy. In the absence of a quorum for the transaction of business, any meeting may
be adjourned from time to time. The stockholders present at a duly called or held meeting may continue to do business until adjournment,
notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Our Chairman of the Board or, in his absence,
any other director designated from time to time by the board of directors, shall preside at all meetings of stockholders.
Preferred Stock
Our Board of Directors has the authority, without action by our stockholders, to designate
and issue up to 20,000,000 shares of preferred stock in one or more series or classes and to designate the rights, preferences
and privileges of each series or class, which may be greater than the rights of our common stock. The Board’s authority to
issue preferred stock without stockholder approval could make it more difficult for a third party to acquire control of our company,
and could discourage such attempt.
Information regarding the terms and outstanding shares of our current classes of preferred
stock are included in the materials incorporated by reference in this prospectus.
Anti-Takeover Provisions
Delaware Law
We are subject to Section 203 of the Delaware General Corporation Law. This provision
generally prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period
of three years following the date the stockholder became an interested stockholder, unless:
|
•
|
prior to such date, the board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;
|
|
•
|
upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned by persons who are directors and also officers and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
|
|
•
|
on or subsequent to such date, the business combination is approved by the board of directors and authorized at an annual meeting or special meeting of stockholders and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.
|
Section 203 defines a business combination to include:
|
•
|
any merger or consolidation involving the corporation and the interested stockholder;
|
|
•
|
any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;
|
|
•
|
subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;
|
|
•
|
any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or
|
|
•
|
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.
|
In general, Section 203 defines an “interested stockholder” as any entity
or person beneficially owning 15% or more of the outstanding voting stock of a corporation, or an affiliate or associate of the
corporation and was the owner of 15% or more of the outstanding voting stock of a corporation at any time within three years prior
to the time of determination of interested stockholder status; and any entity or person affiliated with or controlling or controlled
by such entity or person.
These statutory provisions could delay or frustrate the removal of incumbent directors
or a change in control of our company. They could also discourage, impede, or prevent a merger, tender offer, or proxy contest,
even if such event would be favorable to the interests of stockholders. In addition, note that while Delaware law permits companies
to opt out of its business combination statute, our Certificate of Incorporation does not include this opt-out provision.
Certificate of Incorporation and Bylaws
Our current Certificate of Incorporation authorizes the issuance of “blank check”
preferred stock that could be issued by our Board of Directors to defend against a takeover attempt. See “Preferred Stock”
above.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is Corporate Stock Transfer, Inc.
Listing
The shares of our common stock are listed on The Nasdaq Capital Market under the symbol
“POAI.” On October 28, 2019, the last reported sale price per share for our common stock as reported by The Nasdaq
Capital Market was $4.02 (adjusted to reflect the Reverse Split).
THE OFFERING
The selling stockholder may offer and resell up to 1,139,423 shares of our common stock,
par value $0.01 per share, pursuant to this prospectus. Such shares represent certain shares of our common stock that Oasis Capital
has agreed to purchase from us pursuant to the terms and conditions of an Equity Purchase Agreement we entered into with Oasis
Capital on October 24, 2019, which are described below.
Equity Purchase Agreement and Registration Rights Agreement with
Oasis Capital, LLC
Subject to the terms and conditions of the Equity Purchase Agreement, we have the right
to “put,” or sell, up to $15,000,000 worth of shares of our common stock to Oasis Capital (the “Equity Line”).
Oasis Capital’s purchase commitment will automatically terminate on the earlier of (a) the date on which Oasis Capital shall
have Put Shares for an aggregate purchase price of $15,000,000, (b) October 24, 2022 and (c) written notice of termination by the
Company to Oasis Capital (which shall not occur at any time that Oasis Capital holds any of the Put Shares)... We have no obligation
to sell any shares under the Equity Purchase Agreement.
In consideration for Oasis Capital’s execution and delivery of, and performance
under the Equity Purchase Agreement, the Company also issued to Oasis Capital 104,652 shares of our common stock (the “Commitment
Shares”).
Under the terms of the Equity Purchase Agreement, Oasis Capital will not be obligated
to purchase Put Shares unless and until certain conditions (“Closing Conditions”) are met, including but not limited
to a registration statement on Form S-1 being effective which registers Oasis Capital’s resale of any Put Shares purchased
by it under the Equity Line and the Commitment Shares (together, the “Registrable Securities”). The registration statement
of which this prospectus is a part, upon effectiveness, is intended to satisfy this Closing Condition.
From time to time during the Commitment Period, provided that the Closing Conditions
are satisfied, we may, in our sole discretion, provide Oasis Capital with a put notice (each, a “Put Notice”), to purchase
a specified number of Put Shares. Each Put Notice may be either an Option 1 Put Notice or an Option 2 Put Notice.
Subject to certain limitations and conditions, an “Option 1 Put Notice” will
require Oasis Capital to purchase the specified number of Put Shares up to the Option 1 Maximum Put Amount. The “Option 1
Maximum Put Amount” means: (a) if, on the trading day when the Put Notice is delivered (the “Put Date”), the
closing bid price of our common stock on Nasdaq is below $10.00, then “Option 1 Maximum Put Amount” shall mean the
lesser of (i) 10,000 shares, or (ii) twenty percent (20%) of the average trading volume of our common stock in the ten (10) trading
days immediately preceding the respective Put Date (the “Average Daily Trading Volume”); and (b) if, on the Put Date,
the closing bid price of our common stock on Nasdaq is $10.00 or greater but less than $15.00, then “Option 1 Maximum Put
Amount” shall mean the lesser of (i) 12,500 shares, or (ii) twenty percent (20%) of the Average Daily Trading Volume; and
(c) if, on the Put Date, the closing bid price of our common stock on Nasdaq is $15.00 or greater but less than $20.00, then “Option
1 Maximum Put Amount” shall mean the lesser of (i) 15,000 shares, or (ii) twenty percent (20%) of the Average Daily Trading
Volume; and (d) if, on the Put Date, the closing bid price of our common stock on Nasdaq is $20.00 or greater, then “Option
1 Maximum Put Amount” shall mean the lesser of (i) 20,000 shares, or (ii) twenty percent (20%) of the Average Daily Trading
Volume. The purchase price (the “Option 1 Purchase Price”) will be equal to the lesser of (i) the one (1) lowest traded
price of our common stock on Nasdaq on the date on which Oasis Capital receives the Put Shares (the “Clearing Date”),
or (ii) the average of the three (3) lowest closing sale prices of our common stock on Nasdaq during the twelve (12) consecutive
trading days immediately preceding the Clearing Date associated with the applicable Put Notice during which the Option 1 Purchase
Price of our common stock is valued.
The Company may only deliver an Option 2 Put Notice if an Option 1 Put has been previously
and effectively processed and its clearing date is the same day as the Put Notice for the subject Option 2 Put. Subject to certain
other limitations and conditions, an “Option 2 Put Notice” will require Oasis Capital to purchase the specified number
of Put Shares up to up to the Option 2 Maximum Put Amount. The “Option 2 Maximum Put Amount” means the lesser of (i)
such amount that equals ten percent (10%) of the daily trading volume of our common stock on the Put Date, and (ii) Two Hundred
Thousand Dollars ($200,000.00). The purchase price (the “Option 2 Purchase Price”) will be equal to the lesser of (i)
91% of the one (1) lowest traded price of our common stock on Nasdaq during the ten (10) consecutive trading days immediately preceding
the trading day associated with the applicable Put Notice during which the Option 2 Purchase Price of our common stock is valued,
or (ii) 93% of the volume weighted average price on the Clearing Date, or (iii) 93% of the closing bid price of our common stock
on Nasdaq on the Clearing Date.
In connection with the Equity Purchase Agreement, on October 24, 2019, we also entered
into Registration Rights Agreement (the “Registration Rights Agreement,” and together with the Equity Purchase Agreement,
are referred to herein as the “Transaction Documents”) with Oasis Capital requiring us to prepare and file a registration
statement on Form S-1 (the “Initial Registration Statement”) registering the resale by Oasis Capital of the Registrable
Securities by October 29, 2019. The Company is obligated to use its reasonable best efforts to have the Initial Registration Statement
and any amendment thereto declared effective by the SEC at the earliest possible date. In the event the number of shares available
under the Initial Registration Statement is insufficient to cover all of the Registrable Securities, the Company must amend the
Initial Registration Statement or file a new registration statement (collectively, “Registration Statements”), so as
to cover all of the Registrable Securities as soon as practicable, but in any event not later than ten (10) business days after
the necessity therefor arises, subject to any limits that may be imposed by the SEC pursuant to Rule 415 under the Securities Act
of 1933, as amended. As explained above, the effectiveness of the Initial Registration Statement is a condition precedent to our
ability to sell Put Shares to Oasis Capital under the Equity Purchase Agreement. We do not have the obligation to sell any Put
Shares to Oasis Capital.
The Company is obligated to use reasonable best efforts to keep all Registration Statements
effective, including but not limited to pursuant to Rule 415 promulgated under the Securities Act and available for the resale
by Oasis Capital of all of the Registrable Securities covered thereby at all times until the earlier of (i) the date as of which
Oasis Capital may sell all of the Registrable Securities without restriction pursuant to Rule 144 promulgated under the Securities
Act without any restrictions (including any restrictions under Rule 144(c) or Rule 144(i)) and (ii) the date on which Oasis Capital
shall have sold all the Registrable Securities covered thereby and no Put Shares remain issuable under the Equity Purchase Agreement.
The 1,139,423 shares being offered pursuant to this prospectus by Oasis Capital represent
one third of the shares of our common stock issued and outstanding held by non-affiliates of our Company as of October 28, 2019.
These shares include (i) the 104,652 Commitment Shares and (ii) 1,034,771 shares that may be sold as Put Shares to Oasis Capital.
The Transaction Documents contain covenants, representations and warranties of our Company
and Oasis Capital that are typical for transactions of this type. Oasis Capital also agreed that neither it nor any affiliate acting
on Oasis Capital’s behalf or pursuant to any understanding with Oasis Capital, will execute any short sales during the three-year
term of the Equity Purchase Agreement.
In addition, we and Oasis Capital have granted each other customary indemnification rights
in connection with the Equity Purchase Agreement.
We intend to sell Oasis Capital periodically shares of our common stock under the Equity
Purchase Agreement and Oasis Capital may, in turn, sell such shares to investors in the market at the market price or at negotiated
prices. This may cause our stock price to decline, which will require us to issue increasing numbers of common shares to Oasis
Capital to raise the intended amount of funds, as our stock price declines.
Likelihood of Accessing the Full Amount of the Equity Line
Notwithstanding that the Equity Line is in an amount of $15,000,000, we anticipate that
the actual likelihood that we will be able to access the full amount of the Equity Line is low due to several factors, including
that our ability to access the Equity Line is impacted by our average daily trading volume, which may limit the maximum dollar
amount of each put we deliver to Oasis Capital, and our stock price. Our use of the Equity Line will continue to be limited and
restricted if our share trading volume or and market price of our stock continue at their current levels or decrease further in
the future from the volume and stock prices reported over the past year. Further, if the price of our stock remains at $4.02 per
share (which represents the last reported sale price of the shares of our common stock as reported on the Nasdaq Capital Market
on October 28, 2019), the sale by Oasis Capital of all 1,034,771 of the Put Shares that are registered in this prospectus would
mean we would receive only approximately $4,159,779 from our sale of the shares under the Equity Line. Our ability to issue shares
in excess of the 1,034,771Put Shares covered by the registration statement of which this prospectus is a part will be subject to
our filing a subsequent registration statement with the SEC and the SEC declaring it effective.
In addition, because our ability to deliver puts to Oasis Capital under the Equity Purchase
Agreement is subject to a number of conditions, there is no guarantee that we will receive all or any portion of the $15,000,000
that is available to us under the Equity Line.
SELLING STOCKHOLDER
This prospectus covers the resale by the selling stockholder or its permitted transferees
of up to 1,139,423 shares that have been or may be issued by us to Oasis Capital under the Equity Purchase Agreement. Oasis Capital
is an “underwriter” within the meaning of the Securities Act in connection with its resale of our common stock pursuant
to this prospectus. The selling stockholder has not had any position or office, or other material relationship with us or any of
our affiliates over the past three years. The following table sets forth certain information regarding the beneficial ownership
of shares of common stock by the selling stockholder as of October 28, 2019 and the number of shares of our common stock being
offered pursuant to this prospectus.
The table below (i) lists the selling stockholder and other information regarding the
beneficial ownership (except with respect to the totals in Column 2, as determined under Section 13(d) of the Exchange Act and
the rules and regulations thereunder) of our common stock by the selling stockholder; (ii) have been prepared based upon information
furnished to us by the selling stockholder; and (iii) to our knowledge, is accurate as of the date of this prospectus. The selling
stockholder may sell all, some or none of their shares in this offering. The selling stockholder identified in the table below
may have sold, transferred or otherwise disposed of some or all of its shares since the date of this prospectus in transactions
exempt from or not subject to the registration requirements of the Securities Act. Information concerning the selling stockholder
may change from time to time and, if necessary, we will amend or supplement this prospectus accordingly and as required.
|
|
Shares beneficially
|
|
|
|
Number of shares to be
beneficially
owned and percentage of
beneficial
ownership after the offering(1)(2)
|
Name of selling
stockholder
|
|
owned as of the date
of this prospectus(1)
|
|
Number of shares
being offered
|
|
Number of
shares
|
|
Percentage of
class (3)
|
Oasis Capital, LLC
|
|
|
194,009(4)
|
|
|
|
1,139,423(5)
|
|
|
|
194,009(6)
|
|
|
|
4.99%
|
|
(1)
|
Beneficial ownership is determined in accordance with SEC rules
and generally includes voting or investment power with respect to shares of common stock. Shares of common stock subject to options
and warrants currently exercisable, or exercisable within 60 days, are counted as outstanding for computing the percentage of the
person holding such options or warrants but are not counted as outstanding for computing the percentage of any other person.
|
(2)
|
The amount and percentage of shares of our common stock that will be beneficially owned by the selling stockholder after completion of the offering assume that they will sell all shares of our common stock being offered pursuant to this prospectus.
|
|
|
|
(3)
|
Based on 3,887,957 shares of our common stock issued and outstanding as of October 28, 2019. All shares of our common stock being offered pursuant to this prospectus by the selling stockholder are counted as outstanding for computing the percentage beneficial ownership of such selling stockholder.
|
(4)
|
Includes 113,509 shares owned directly by Oasis Capital and 15,000 shares owned directly by L2 Capital, LLC, which is part of a group with Oasis Capital, LLC. Adam Long has sole voting and investment control over shares owned by Oasis Capital and L2 Capital. The indicated amount represents 4.99% of the outstanding shares of our common stock as of October 28, 2019, which includes shares that may be purchased up to beneficial ownership limitations as follows: (a) up to 75,374 shares that may be purchased by L2 Capital under warrants that may be exercised within 60 days, subject to a 4.99% beneficial ownership limitation, and (b) up to 103,734 shares that may be issued to L2 Capital under a convertible note (limited by an applicable share cap), subject to a 4.99% beneficial ownership limitation. Oasis Capital is not currently considered to beneficially own the shares it may purchase under the equity purchase agreement, because it does not control whether it purchases any or all of such shares. In addition, Oasis Capital is not considered to beneficially own up to 68,237 shares it may purchase pursuant to warrants it received in October 2019, which are not exercisable within 60 days.
|
|
|
(5)
|
Represents one-third of the shares of our common stock held by non-affiliates of our Company as of October 28, 2019.
|
|
|
(6)
|
Includes 8,858 shares owned directly by Oasis Capital after the offering and 15,000 shares owned directly by L2 Capital, LLC, which is part of a group with Oasis Capital, LLC. Adam Long has sole voting and investment control over shares owned by Oasis Capital and L2 Capital. The indicated amount represents 4.99% of the outstanding shares of our common stock as of October 28, 2019, which includes shares that may be purchased up to beneficial ownership limitations as follows: (a) up to 75,374 shares that may be purchased by L2 Capital under warrants that may be exercised within 60 days, subject to a 4.99% beneficial ownership limitation, and (b) up to 103,734 shares that may be issued to L2 Capital under a convertible note (limited by an applicable share cap), subject to a 4.99% beneficial ownership limitation. Oasis Capital is not considered to beneficially own up to 68,237 shares it may purchase pursuant to warrants it received in October 2019, which are not exercisable within 60 days.
|
PLAN OF DISTRIBUTION
The selling stockholder or its permitted transferees may, from time to time, sell any
or all of shares of our common stock covered hereby on the Nasdaq stock market, or any other stock exchange, market or trading
facility on which the shares are traded or in private transactions. The selling stockholder may sell all or a portion of the shares
being offered pursuant to this prospectus at fixed prices, at prevailing market prices at the time of sale, at varying prices or
at negotiated prices. The selling stockholder may use any one or more of the following methods when selling securities:
|
●
|
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
|
|
●
|
block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
|
|
●
|
purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
|
|
●
|
an exchange distribution in accordance with the rules of the applicable exchange;
|
|
●
|
privately negotiated transactions;
|
|
●
|
in transactions through broker-dealers that agree with the selling stockholder to sell a specified number of such securities at a stipulated price per security;
|
|
●
|
through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
|
|
●
|
a combination of any such methods of sale; or
|
|
●
|
any other method permitted pursuant to applicable law.
|
The selling stockholder may also sell securities under Rule 144 under the Securities
Act, if available, rather than under this prospectus.
Broker-dealers engaged by the selling stockholder may arrange for other brokers-dealers
to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholder (or, if any broker-dealer
acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, provided such amounts are in compliance
with FINRA Rule 2121. Discounts, concessions, commissions and similar selling expenses, if any, that can be attributed to the sale
of common stock will be paid by the selling stockholder and/or the purchasers.
Oasis Capital is an underwriter within the meaning of the Securities Act and any broker-dealers
or agents that are involved in selling the shares may be deemed to be “underwriters” within the meaning of the Securities
Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the
resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Because
Oasis Capital is an underwriter within the meaning of the Securities Act, it will be subject to the prospectus delivery requirements
of the Securities Act.
Under applicable rules and regulations under the Exchange Act, any person engaged in
the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common
stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition,
the selling stockholder will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder,
including Regulation M, which may limit the timing of purchases and sales of securities of the common stock by the selling stockholder
or any other person. We will make copies of this prospectus available to the selling security holders and have informed them of
the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale.
Although Oasis Capital has agreed not to enter into any “short sales” of
our common stock, sales after delivery of a put notice of a number of shares reasonably expected to be purchased under a put notice
shall not be deemed a “short sale.” Accordingly, Oasis Capital may enter into arrangements it deems appropriate with
respect to sales of shares of our common stock after it receives a put notice under the Equity Purchase Agreement so long as such
sales or arrangements do not involve more than the number of put shares reasonably expected to be purchased by Oasis Capital under
such put notice.
LEGAL MATTERS
The validity of any securities offered from time to time by this prospectus and any related
prospectus supplement will be passed upon by Maslon LLP, Minneapolis, Minnesota. If legal matters in connection with offerings
made pursuant to this prospectus and any related prospectus supplement are passed upon by counsel to underwriters, dealers or agents,
if any, such counsel will be named in the prospectus supplement related to such offering.
EXPERTS
The consolidated financial statements for the fiscal year ended December 31, 2018 incorporated
in this Prospectus by reference from the Company's Annual Report on Form 10-K for the year ended December 31, 2018, have been audited
by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report, which is incorporated
herein by reference (which report expresses an unqualified opinion on the consolidated financial statements and includes an explanatory
paragraph relating to the substantial doubt about the Company’s ability to continue as a going concern as described in Note
1 to the financial statements). Such consolidated financial statements have been so incorporated in reliance upon the report of
such firm given upon their authority as experts in accounting and auditing.
Our financial statements for the fiscal year ended December 31, 2017 incorporated by
reference in this prospectus have been so incorporated in reliance on the report of our former auditors, Olsen Thielen & Co.,
Ltd., certified public accountants registered with the Public Company Accounting Oversight Board. The financial statements of Helomics
Holding Corporation for the fiscal years ended December 31, 2018 and 2017, as restated, incorporated by reference in this prospectus
have been so incorporated in reliance on the report of Schneider Downs & Co., Inc., certified public accountants registered
with the Public Company Accounting Oversight Board, as auditor for Helomics Holding Corporation prior to the acquisition by the
Company
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements and other information
with the SEC. We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities
we are offering under this prospectus. This prospectus does not contain all of the information set forth in the registration statement
and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under
this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration
statement. Reports filed with the SEC pursuant to the Exchange Act, including proxy statements, annual and quarterly reports, and
other reports filed by the Company can be inspected and copied at the public reference facilities maintained by the SEC at the
Headquarters Office, 100 F Street N.E., Room 1580, Washington, D.C. 20549. The reader may obtain information on the operation of
the public reference room by calling the SEC at 1-800-SEC-0330. The reader can request copies of these documents upon payment of
a duplicating fee by writing to the SEC. Our filings are also available on the SEC’s internet site at http://www.sec.gov.
and the Company’s website at www.precisiontherapeutics.com. Information on any Company website, any subsection, page, or
other subdivision of any Company website, or any website linked to by content on any Company website, is not part of this prospectus
and you should not rely on that information unless that information is also in this prospectus or incorporated by reference in
this prospectus.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to “incorporate by reference” information into this prospectus,
which means that we can disclose important information to you by referring you to another document filed separately with the SEC.
The documents incorporated by reference into this prospectus contain important information that you should read about us. The following
documents are incorporated by reference into this prospectus:
We are allowed to incorporate by reference information contained in documents that we
file with the SEC. This means that we can disclose important information to you by referring you to those documents and that the
information in this prospectus is not complete and you should read the information incorporated by reference for more detail. We
incorporate by reference in two ways. First, we list certain documents that we have already filed with the SEC. The information
in these documents is considered part of this prospectus. Second, the information in documents that we file in the future will
update and supersede the current information in, and incorporated by reference in, this prospectus.
We incorporate by reference the documents listed below and any future filings we will
make with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than information furnished in Current Reports
on Form 8-K filed under Item 2.02 or 7.01 of such form unless such form expressly provides to the contrary):
|
·
|
Our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and Amendment to Form 10-K filed on April 2, 2019;
|
|
·
|
Quarterly Reports on Form 10-Q for the quarters ended March 31, 2019, June 30, 2019 and September 30, 2019;
|
|
·
|
Current Reports on Form 8-K filed November 15, 2019, October 28, 2019, October 24,
2019, October 10, 2019, September 30, 2019, September 26, 2019, September 26, 2019 (amendment), August 19, 2019, July 11,
2019, June 19, 2019, June 18, 2019 (amendment), June 13, 2019, June 4, 2019, May 23, 2019, May 17, 2019, May 15, 2019, May 8,
2019, April 10, 2019, April 2, 2019, April 1, 2019, March 22, 2019, March 14, 2019, March 8, 2019, March 5, 2019, March 1,
2019, February 26, 2019, February 19, 2019, February 12, 2019, February 7, 2019, January 28, 2019 (amendment), January 25,
2019, January 22, 2019, January 18, 2019, January 17, 2019, January 14, 2019 and January 3, 2019.
|
|
·
|
The description of the Company’s common stock under the caption “Description of Predictive Capital Stock – Common Stock” in the Company’s Amendment No. 2 to Registration Statement on Form S-4 as filed with the SEC on January 24, 2019.
|
We will provide to each person, including any beneficial owner, to whom a prospectus
is delivered, a copy of any or all of the information that has been incorporated by reference in this prospectus but not delivered
with this prospectus. You may request a copy of this information at no cost, by writing or telephoning us at the following address
or telephone number:
Predictive Oncology Inc.
Attention: Corporate Secretary
2915 Commers Drive, Suite 900
Eagan, Minnesota 55121
(651) 389-4800
PREDICTIVE ONCOLOGY INC.
1,139,423 Shares
Common Stock
______________________
PROSPECTUS
______________________
November 19, 2019
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024